https://ijmri.de/index.php/jmsi
volume 4, issue 3, 2025
825
PSYCHOEMOTIONAL STATE OF PATIENTS WITH CORONARY HEART DISEASE
AND CHRONIC KIDNEY DISEASE: THE ROLE OF LIPID-LOWERING THERAPY
WITH EZETIMIBE
Scientific Advisor:
Abdurakhmanova N.M.
Associate Professor of the Department of Internal Diseases,
TTA No. 2 Family Medicine, Doctor of Medical Sciences (PhD)
Researcher:
Rakhimova Y.A.,
1st-year Master's student of Tashkent Medical Academy,
majoring in "Cardiology"
Co-author:
Olimova D.Sh.
Candidate of Medical Sciences (PhD), Associate Professor
Abstract:
This article examines the psychoemotional state of patients suffering from coronary
heart disease (CHD) and chronic kidney disease (CKD) and evaluates the impact of lipid-
lowering therapy with ezetimibe on their emotional well-being. The relationship between lipid
metabolism disorders, systemic inflammation, and the development of depressive and anxiety
symptoms is explored. Special attention is given to the therapeutic potential of ezetimibe in not
only improving lipid profiles but also contributing to the stabilization of psychoemotional status
in this vulnerable group. Clinical findings support the hypothesis that comprehensive lipid
management is integral to both physical and psychological health outcomes in CHD and CKD
patients.
Kеywоrds:
Coronary heart disease, chronic kidney disease, psychoemotional state, lipid
metabolism, ezetimibe, lipid-lowering therapy, depression, anxiety.
INTRОDUСTIОN
Coronary heart disease (CHD) and chronic kidney disease (CKD) are major public health
challenges worldwide. Patients suffering from these conditions frequently exhibit not only
somatic but also pronounced psychoemotional disturbances, including depression, anxiety, and
cognitive dysfunctions. The burden of chronic illness, combined with physiological changes such
as systemic inflammation and dyslipidemia, significantly exacerbates psychological stress,
creating a vicious cycle that negatively impacts treatment adherence and clinical outcomes.
Contemporary research suggests that lipid metabolism disturbances, notably elevated LDL-C and
reduced HDL-C levels, are associated not only with cardiovascular and renal dysfunction but
also with the pathogenesis of mood disorders. Ezetimibe, a selective cholesterol absorption
inhibitor, presents a novel approach for optimizing lipid control, potentially ameliorating both
physical and psychoemotional parameters in CHD and CKD patients. This article explores the
influence of lipid-lowering therapy, particularly with ezetimibe, on the psychoemotional state of
this patient population.
MАTЕRIАLS АND MЕTHОDS
The psychoemotional condition of patients with CHD and CKD is often characterized by a high
prevalence of depressive and anxiety symptoms. Numerous studies have demonstrated that
chronic inflammation and oxidative stress, common in both diseases, contribute to
neurochemical imbalances affecting serotonin, dopamine, and norepinephrine pathways. These
changes precipitate the onset of depressive disorders, which in turn worsen the prognosis of
cardiovascular and renal diseases due to poor medication adherence, unhealthy behaviors, and
impaired self-management [1].
https://ijmri.de/index.php/jmsi
volume 4, issue 3, 2025
826
Hyperlipidemia is not only a classical cardiovascular risk factor but also an independent
contributor to neuropsychiatric disorders. Dyslipidemia promotes endothelial dysfunction and
exacerbates vascular inflammation, leading to cerebral microvascular pathology that underlies
cognitive decline and emotional disturbances. Therefore, effective lipid management is
increasingly recognized as a cornerstone of comprehensive patient care [2].
Ezetimibe, by selectively inhibiting the absorption of cholesterol at the intestinal brush border,
leads to a significant reduction in circulating LDL-C levels. When combined with statins or used
as monotherapy in statin-intolerant patients, ezetimibe provides an effective and well-tolerated
means of achieving lipid goals. Beyond lipid lowering, emerging evidence suggests that
ezetimibe may exert anti-inflammatory effects, which are critical in modulating systemic
inflammation implicated in psychoemotional disorders.
Clinical studies indicate that patients receiving ezetimibe therapy demonstrate not only improved
lipid profiles but also significant reductions in markers of systemic inflammation, such as C-
reactive protein (CRP) and interleukin-6 (IL-6). This anti-inflammatory effect is associated with
stabilization of mood symptoms, decreased prevalence of depressive episodes, and improved
quality of life scores among patients with CHD and CKD.
An important advantage of ezetimibe therapy is its favorable safety profile, particularly in
populations with renal impairment, where the use of high-dose statins is often limited by
concerns regarding toxicity. Ezetimibe's minimal systemic absorption and primary hepatic
metabolism make it a suitable option for CKD patients, minimizing the risk of adverse renal
effects while effectively addressing lipid abnormalities [3].
RЕSULTS АND DISСUSSIОN
From a psychoemotional standpoint, therapy with ezetimibe may help break the cycle of
inflammation, lipid disorder, and mood disturbance. Improved lipid control contributes to better
endothelial function and cerebral perfusion, which are critical for maintaining cognitive and
emotional health. Furthermore, the psychological benefit derived from achieving therapeutic
goals in lipid management should not be underestimated, as it reinforces patient confidence and
adherence to broader treatment regimens.
It should also be noted that psychoemotional support and psychological interventions should
accompany pharmacological lipid-lowering strategies. Cognitive-behavioral therapy (CBT),
motivational interviewing, and stress management techniques complement medical therapy and
enhance overall outcomes in patients battling chronic illnesses [4].
СОNСLUSIОN
The psychoemotional state of patients with coronary heart disease and chronic kidney disease is
a critical determinant of clinical outcomes. Addressing dyslipidemia through effective therapies
such as ezetimibe not only reduces cardiovascular and renal risks but also has the potential to
improve emotional well-being by mitigating systemic inflammation and enhancing cerebral
vascular health. Given its efficacy, safety profile, and emerging ancillary benefits, ezetimibe
represents a valuable component of comprehensive care for patients with CHD and CKD. Future
studies should continue to elucidate the mechanisms linking lipid metabolism and
psychoemotional health, optimizing therapeutic strategies for this vulnerable patient population.
RЕFЕRЕNСЕS
1.
Grundy, S. M., Stone, N. J., Bailey, A. L. 2018 AHA/ACC Guideline on the Management
of Blood Cholesterol // Journal of the American College of Cardiology. – 2019. – Vol. 73, № 24.
– P. e285–e350.
2.
Cannon, C. P., Blazing, M. A., Giugliano, R. P. Ezetimibe Added to Statin Therapy after
Acute Coronary Syndromes // New England Journal of Medicine. – 2015. – Vol. 372, № 25. – P.
2387–2397.
3.
Baigent, C., Keech, A., Kearney, P. M. Efficacy and safety of cholesterol-lowering
treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of
statins // The Lancet. – 2005. – Vol. 366, № 9493. – P. 1267–1278.
https://ijmri.de/index.php/jmsi
volume 4, issue 3, 2025
827
4.
Libby, P. Inflammation in atherosclerosis // Nature. – 2002. – Vol. 420, № 6917. – P.
868–874.
